Telangana secures over Rs 36,000 crore in life sciences investments, genome valley leads the way
Genome Valley at the center of this growth.
Notable investments include a Rs. 2,000 crore joint venture between European company KrKA and Laurus Labs to establish pharmaceutical finished products and biopharmaceutical manufacturing facilities in Genome Valley. In addition, Laurus Labs has inaugurated an R&D center with an investment of Rs. 250 crore. Together, these projects are expected to create over 2,800 jobs.
Another significant development is the partnership between Japanese pharmaceutical giant Takeda and Biological E, aimed at manufacturing 5 crore doses of the Dengue vaccine annually from Genome Valley. This collaboration positions Hyderabad at the forefront of the global fight against dengue, further solidifying its reputation as the “vaccine capital of the world.”
“We have witnessed a surge of investments from several international and domestic companies, who have chosen Telangana as their gateway to India’s rapidly growing life sciences ecosystem. From pharmaceutical manufacturing and R&D centers to GCC innovation hubs, these investments across the life sciences value chain make Telangana an undisputed leader in this space globally,” said Duddilla Sridhar Babu, Minister of Industries and Commerce, Government of Telangana.
These investments are expected to create 51,000 direct jobs and an estimated 1,50,000 indirect jobs, reaffirming Telangana’s status as a powerhouse in the global life sciences industry.
Web Development
Advanced C++ Mastery: OOPs and Template Techniques
By — Metla Sudha Sekhar, IT
